The company announced a new collaboration with the University of Alberta to develop drugs for use against SARS-Cov2

The company announced a new collaboration with the University of Alberta to develop drugs for use against SARS-Cov2

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.

The company announced a new collaboration with the University of Alberta to develop drugs for use against SARS-Cov2

https://www.globenewswire.com/news-release/2022/05/18/2445830/28908/en/Tonix-Pharmaceuticals-Extends-Research-Collaboration-with-the-University-of-Alberta-to-Develop-Antiviral-Drugs-Against-SARS-CoV-2.html

NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a license agreement and extended a research collaboration with the University of Alberta, a leading Canadian research university, focused on identifying and testing broad-spectrum antiviral drugs against future variants of SARS-CoV-2 and other emerging viruses.

https://finance.yahoo.com/news/indaptus-therapeutics-announces-fda-clearance-110000411.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist